These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26925666)

  • 1. Safety Analysis of Adjuvant Chemotherapy with Docetaxel Administered with or without Anthracyclines to Early Stage Breast Cancer Patients: Combined Results from the Asia- Pacific Breast Initiatives I and II.
    Kim SB; Sayeed A; Villalon AH; Shen ZZ; Yau TK; Shah MA; Hou MF; Thuan TV; Ba DN; Chao TY
    Asian Pac J Cancer Prev; 2016; 17(2):697-702. PubMed ID: 26925666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel-based adjuvant therapy for breast cancer patients in Asia-Pacific region: Results from 5 years follow-up on Asia-Pacific Breast Initiative-I.
    Kim SB; Sayeed A; Villalon AH; Shen ZZ; Shah MA; Hou MF; Nguyen Ba D
    Asia Pac J Clin Oncol; 2016 Jun; 12(2):125-32. PubMed ID: 26891467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety Results of Docetaxel-(Taxotere®)-Based Chemotherapy in Early Breast Cancer Patients of Asia-Pacific Region: Asia-Pacific Breast Initiative II.
    Kim SB; Kok YT; Thuan TV; Chao TY; Shen ZZ
    J Breast Cancer; 2015 Dec; 18(4):356-64. PubMed ID: 26770242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy Among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study.
    Xie H; Liu J; Yu S; Chen Y; Zheng M; Deng Y; Wang S; Jiang J; Li Y; Li H; Kang H; Zhang C; Zhang GJ; Su F; Cheng A; Wang S
    Adv Ther; 2019 Jan; 36(1):131-146. PubMed ID: 30511279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.
    Jones SE; Collea R; Paul D; Sedlacek S; Favret AM; Gore I; Lindquist DL; Holmes FA; Allison MAK; Brooks BD; Portillo RM; Vukelja SJ; Steinberg MS; Stokoe C; Crockett MW; Wang Y; Asmar L; Robert NJ; O'Shaughnessy J
    Lancet Oncol; 2013 Oct; 14(11):1121-1128. PubMed ID: 24007746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].
    Yuan P; Xu BH; Wang JY; Ma F; Li Q; Zhang P; Fan Y; Li Q; Wang WM
    Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):465-8. PubMed ID: 22967451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
    Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
    Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
    Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
    Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
    Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
    J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.
    Mavroudis D; Saloustros E; Boukovinas I; Papakotoulas P; Kakolyris S; Ziras N; Christophylakis C; Kentepozidis N; Fountzilas G; Rigas G; Varthalitis I; Kalbakis K; Agelaki S; Hatzidaki D; Georgoulias V
    Br J Cancer; 2017 Jul; 117(2):164-170. PubMed ID: 28641315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.
    Yardley DA; Hart L; Waterhouse D; Whorf R; Drosick DR; Murphy P; Badarinath S; Daniel BR; Childs BH; Burris H
    Breast Cancer Res Treat; 2013 Dec; 142(3):655-65. PubMed ID: 24253810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients.
    Sanna G; Pestrin M; Zafarana E; Biagioni C; Cavaciocchi D; Turner N; Di Leo A; Biganzoli L
    Breast; 2013 Oct; 22(5):926-32. PubMed ID: 23707082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study.
    Cardoso F; Ferreira Filho AF; Crown J; Dolci S; Paesmans M; Riva A; Di Leo A; Piccart MJ
    Anticancer Res; 2001; 21(1B):789-95. PubMed ID: 11299845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
    Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
    Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
    Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
    Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
    Kim R; Osaki A; Tanabe K; Toge T
    Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant trastuzumab for 6 months is effective in patients with HER2-positive stage II or III breast cancer.
    Tai CJ; Pan CK; Chen CS; Hung CS; Wu CH; Chiou HY
    Asian Pac J Cancer Prev; 2013; 14(3):1981-4. PubMed ID: 23679303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.
    Ramaswamy B; Povoski SP; Rhoades C; Allen J; Hauger M; Young D; Burak W; Farrar W; Yee L; Kendra K; Somasundaram S; Orlowski RZ; Shapiro CL
    Breast Cancer Res Treat; 2005 Sep; 93(1):67-74. PubMed ID: 16184461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer.
    Cresta S; Grasselli G; Mansutti M; Martoni A; Lelli G; Capri G; Buzzi F; Cuna GR; Jirillo A; Terzoli E; Frevola L; Tarenzi E; Sguotti C; Azli N; Murawsky M; Gianni L
    Ann Oncol; 2004 Mar; 15(3):433-9. PubMed ID: 14998845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.